Mirna Therapeutics Inc, a biotechnology company that specializes in growth and commercialization of miRNA therapeutics appointed Clay Siegall, CEO, president, co-founder and chairperson of Seattle Genetics’ board of directors as its board of directors’ external director. This appointment was due to Siegall’s vast experience in the pharmaceutical sector and his achievements in developing leading oncology company. Mirna Therapeutics is situated in Austin, Texas.
miRNAs are about 20-25 nucleotides long that interact with messenger RNAs to affect the gene expression. miRNAs coordinate the expression of several genes and guide proper embryonic growth, inflammation, cellular growth, immunity, and proliferation. This helps meet patients’ cancer needs.
About Seattle Genetics
Seattle Genetics was founded in 1998 as a foundation of precise research, scientific innovation, as well as drug development practices. The company has a mission to help cancer patients. Seattle Genetics has acquired different strategic licenses to practice ADC technology through a partnership with companies such as GlaxoSmithKline, Genentech (Roche), Pfizer and Abbvie. Dr. Siegall, the company’s co-founder, CEO, president and chairperson board of directors has led the company to capital-raising activities, to attaining over $675 million via private and public funding, as well as the firm’s first public offering back in 2001.
About Clay Siegall
Clay B. Siegall, Ph.D. is currently the CEO and chairman, Seattle Genetics, Inc and co-founded this company in 1998. Dr.Siegall pursued Bachelor of Science, Zoology in the University of Maryland, and acquired a Ph.D. in genetics from The George Washington University. He has led Seattle Genetics to its present leadership point in the development of antibody-drug conjugates for cancer treatment.
Dr.Siegall has served in different capacities including:
• President and CEO, Seattle Genetics from 1998 to present.
• Chairman, the board of directors, Alder Biopharmaceuticals, Inc from 2006 to present.
• Chairman, the board of directors, Mirna Therapeutics, Inc from 2013 to present.
• Director for the board of directors, Ultragenyx Pharmaceutical from 2014 to present.